Study Design Our study was a retrospective case-control review that included patients admitted to the hospital over a 10-month period. All study subjects developed diarrhea and were subsequently tested for the presence of C. difficile toxin A in the stool, as determined by an enhanced optical immunoassay. The study took place in a 420-bed tertiary [...]
ABSTRACT Purpose: We analyzed the relationship between the use of proton pump inhibitors (PPIs) and the development of Clostridium difficile-associated diarrhea (CDAD) in hospitalized patients . Methods: We conducted a retrospective case-control study in a 420-bed tertiary hospital serving a rural population in a 10-county region. We identified all patients in the hospital who had [...]
A study by Kramer and associates also evaluated the efficacy of paliperidone ER in a multiphase trial. In an eight-week run-in phase, 530 patients were hospitalized and received open-label paliperi-done. Dosing was flexible, starting at 9 mg once daily, and the dose could be adjusted between 3 and 15 mg once daily. The most commonly [...]
INDICATIONS Paliperidone was approved in December 2006 for the acute treatment of schizophrenia and for the long-term maintenance treatment of schizophrenia in April 2007.
The psychotropic agent paliperidone is chemically related to risperidone. This active metabolite belongs to the ben-zisoxazole derivative class and contains a racemic mixture of (+) and (-) enan-tiomers of paliperidone. It is available in strengths of 3, 6, or 9 mg.
INTRODUCTION Schizophrenia is a chronic mental illness that affects between 0.5% and 1% of the population in the U.S. today. Even though schizophrenic patients characteristically have psychoses, including hallucinations and delusions, this debilitating disease impairs their functional capacity to learn, work, care for themselves, maintain interpersonal relationships, and sustain general living skills. Forty percent to [...]
Crohn’s Disease with Fistula Adalimumab (Humira, Abbott), a fully human monoclonal antibody that targets tumor necrosis factor (TNF), has been found efficacious for inducing and maintaining remission in patients with Crohn’s disease (CD). According to data presented at the meeting, adalimumab offers sustained responses for the 20% to 30% of patients whose course is complicated [...]
© 2008 HIV/AIDS News & Information